387 related articles for article (PubMed ID: 18332869)
1. Retinoblastoma protein modulates gankyrin-MDM2 in regulation of p53 stability and chemosensitivity in cancer cells.
Qiu W; Wu J; Walsh EM; Zhang Y; Chen CY; Fujita J; Xiao ZX
Oncogene; 2008 Jul; 27(29):4034-43. PubMed ID: 18332869
[TBL] [Abstract][Full Text] [Related]
2. The oncoprotein gankyrin binds to MDM2/HDM2, enhancing ubiquitylation and degradation of p53.
Higashitsuji H; Higashitsuji H; Itoh K; Sakurai T; Nagao T; Sumitomo Y; Masuda T; Dawson S; Shimada Y; Mayer RJ; Fujita J
Cancer Cell; 2005 Jul; 8(1):75-87. PubMed ID: 16023600
[TBL] [Abstract][Full Text] [Related]
3. The oncoprotein gankyrin negatively regulates both p53 and RB by enhancing proteasomal degradation.
Higashitsuji H; Liu Y; Mayer RJ; Fujita J
Cell Cycle; 2005 Oct; 4(10):1335-7. PubMed ID: 16177571
[TBL] [Abstract][Full Text] [Related]
4. Gankyrin: an intriguing name for a novel regulator of p53 and RB.
Lozano G; Zambetti GP
Cancer Cell; 2005 Jul; 8(1):3-4. PubMed ID: 16023592
[TBL] [Abstract][Full Text] [Related]
5. Knockdown of HURP inhibits the proliferation of hepacellular carcinoma cells via downregulation of gankyrin and accumulation of p53.
Kuo TC; Chang PY; Huang SF; Chou CK; Chao CC
Biochem Pharmacol; 2012 Mar; 83(6):758-68. PubMed ID: 22230478
[TBL] [Abstract][Full Text] [Related]
6. Targeting retinoblastoma protein for degradation by proteasomes.
Ying H; Xiao ZX
Cell Cycle; 2006 Mar; 5(5):506-8. PubMed ID: 16552188
[TBL] [Abstract][Full Text] [Related]
7. The overexpression of multidrug resistance-associated proteins and gankyrin contribute to arsenic trioxide resistance in liver and gastric cancer cells.
Chen X; Zhang M; Liu LX
Oncol Rep; 2009 Jul; 22(1):73-80. PubMed ID: 19513507
[TBL] [Abstract][Full Text] [Related]
8. Gankyrin: a new oncoprotein and regulator of pRb and p53.
Dawson S; Higashitsuji H; Wilkinson AJ; Fujita J; Mayer RJ
Trends Cell Biol; 2006 May; 16(5):229-33. PubMed ID: 16581249
[TBL] [Abstract][Full Text] [Related]
9. Synthetic Proteins Potently and Selectively Bind the Oncoprotein Gankyrin, Modulate Its Interaction with S6 ATPase, and Suppress Gankyrin/MDM2-Dependent Ubiquitination of p53.
Chapman AM; McNaughton BR
ACS Chem Biol; 2015 Aug; 10(8):1880-6. PubMed ID: 25955581
[TBL] [Abstract][Full Text] [Related]
10. Evidence that proteasome-dependent degradation of the retinoblastoma protein in cells lacking A-type lamins occurs independently of gankyrin and MDM2.
Nitta RT; Smith CL; Kennedy BK
PLoS One; 2007 Sep; 2(9):e963. PubMed ID: 17896003
[TBL] [Abstract][Full Text] [Related]
11. Gankyrin, the 26 S proteasome, the cell cycle and cancer.
Mayer RJ; Fujita J
Biochem Soc Trans; 2006 Nov; 34(Pt 5):746-8. PubMed ID: 17052188
[TBL] [Abstract][Full Text] [Related]
12. MDM2 promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma protein.
Sdek P; Ying H; Chang DL; Qiu W; Zheng H; Touitou R; Allday MJ; Xiao ZX
Mol Cell; 2005 Dec; 20(5):699-708. PubMed ID: 16337594
[TBL] [Abstract][Full Text] [Related]
13. Effects of MdmX on Mdm2-mediated downregulation of pRB.
Uchida C; Miwa S; Isobe T; Kitagawa K; Hattori T; Oda T; Yasuda H; Kitagawa M
FEBS Lett; 2006 Mar; 580(7):1753-8. PubMed ID: 16510145
[TBL] [Abstract][Full Text] [Related]
14. Dual-site regulation of MDM2 E3-ubiquitin ligase activity.
Wallace M; Worrall E; Pettersson S; Hupp TR; Ball KL
Mol Cell; 2006 Jul; 23(2):251-63. PubMed ID: 16857591
[TBL] [Abstract][Full Text] [Related]
15. ARF promotes accumulation of retinoblastoma protein through inhibition of MDM2.
Chang DL; Qiu W; Ying H; Zhang Y; Chen CY; Xiao ZX
Oncogene; 2007 Jul; 26(32):4627-34. PubMed ID: 17297463
[TBL] [Abstract][Full Text] [Related]
16. Functional characterization of human oncoprotein gankyrin in Zebrafish.
Kim SY; Hur W; Choi JE; Kim D; Wang JS; Yoon HY; Piao LS; Yoon SK
Exp Mol Med; 2009 Jan; 41(1):8-16. PubMed ID: 19287195
[TBL] [Abstract][Full Text] [Related]
17. YY1 inhibits the activation of the p53 tumor suppressor in response to genotoxic stress.
Grönroos E; Terentiev AA; Punga T; Ericsson J
Proc Natl Acad Sci U S A; 2004 Aug; 101(33):12165-70. PubMed ID: 15295102
[TBL] [Abstract][Full Text] [Related]
18. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
[TBL] [Abstract][Full Text] [Related]
19. Regulation of p53 and MDM2 activity by MTBP.
Brady M; Vlatkovic N; Boyd MT
Mol Cell Biol; 2005 Jan; 25(2):545-53. PubMed ID: 15632057
[TBL] [Abstract][Full Text] [Related]
20. mdm2: a bridge over the two tumour suppressors, p53 and Rb.
Yap DB; Hsieh JK; Chan FS; Lu X
Oncogene; 1999 Dec; 18(53):7681-9. PubMed ID: 10618708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
